Samara E, Cavanaugh J H, Mukherjee D, Granneman G R
Pharmacokinetics and Biopharmaceutics Department, Abbott Laboratories, Abbott Park, Illinois, USA.
Clin Pharmacokinet. 1995;29 Suppl 2:84-91. doi: 10.2165/00003088-199500292-00012.
A randomised double-blind crossover study was undertaken in 20 healthy adult male volunteers to assess the effects of multiple oral dose administration of zileuton (600mg every 6 hours for 8 days) on the single dose pharmacokinetics of phenytoin 300mg. Serial blood samples were collected up to 72 hours after phenytoin administration and plasma concentrations were determined by high performance liquid chromatography. Pharmacokinetic data were analysed utilising noncompartmental and Michaelis-Menten-based population pharmacokinetic analysis. Zileuton did not significantly alter the peak plasma concentration, time to peak plasma concentration, and area under the plasma concentration-time curve of phenytoin. Moreover, population analysis revealed no significant effect of zileuton on the Michaelis-Menten parameters of phenytoin. Thus, coadministration of multiple doses of zileuton (2.4 g/day) did not significantly affect the single dose pharmacokinetics of phenytoin.
在20名健康成年男性志愿者中进行了一项随机双盲交叉研究,以评估多次口服齐留通(每6小时600mg,共8天)对300mg苯妥英单次给药药代动力学的影响。在苯妥英给药后长达72小时采集系列血样,并用高效液相色谱法测定血浆浓度。利用非房室和基于米氏方程的群体药代动力学分析方法分析药代动力学数据。齐留通未显著改变苯妥英的血浆峰浓度、达峰时间和血浆浓度-时间曲线下面积。此外,群体分析显示齐留通对苯妥英的米氏参数无显著影响。因此,多次给予齐留通(2.4g/天)未显著影响苯妥英的单次给药药代动力学。